Medications Archives

April 9, 2025

Pirtobrutinib for Relapsed CLL After Covalent BTKi Therapy

Pirtobrutinib provides longer progression-free survival and is safer than idelalisib-rituximab and bendamustine-rituximab for treating relapsed CLL.

February 20, 2025

Promising Results in Difficult-to-Treat CLL with Epcoritamab

Epcoritamab, a novel bispecific antibody monotherapy, showed strong results in relapsed / refractory high-risk CLL patients.

October 23, 2024

Solid Results for Epcoritimab for Relapsed / Refractory CLL

Epcoritamab, a bispecific antibody, shows encouraging early results in relapsed / refractory chronic lymphocytic leukemia (CLL) patients.

July 25, 2024

Long-term Outcomes After Lenalidomide plus Rituximab for CLL

With the introduction of BTK inhibitors to treat CLL, there has been no disparity in survival outcomes for patients of different races and ethnicities.

July 13, 2022

Spontaneous Remission of Chronic Lymphocytic Leukemia in a Patient with SARS-CoV-2

This should not be part of anyone’s game plan. Still, it was nice to read that for at least this one 67-year-old asymptomatic CLL patient, a case of COVID-19 associated with low blood counts and a broad spectrum of treatments resulted in his CLL becoming undetectable in his bone

March 21, 2022

Immunotherapeutic Strategies in Chronic Lymphocytic Leukemia: Advances and Challenges

Immunotherapy for chronic lymphocytic leukemia/small lymphocytic lymphoma or CLL / SLL holds the promise of harnessing the body’s immune system to recognize and eliminate cancer.

February 24, 2022

ASH 2021: BRUIN CLL-321: A Phase 3 Open-Label, Randomized Study of Pirtobrutinib Versus Investigator’s Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in BTK Inhibitor Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (Trial in Progress)

Dr. Jeff Sharman and colleagues presented this research at the American Society for Hematology annual meeting held December 2021 (ASH 2021).

February 18, 2022

ASH 2021: Deep Profiling of Chronic Lymphocytic Leukemia (CLL) and Healthy Immune Cells By Mass Cytometry Resolves Impacts of Venetoclax Pressure

Dr. Charis Teh and colleagues presented this research at the American Society for Hematology annual meeting, which was held in December 2021 (ASH 2021). Background: Venetoclax is a highly effective treatment for chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) that works by inhibiting the BCL2 protein. BCL2

February 16, 2022

ASH 2021: SEQUOIA: Results of a Phase 3 Randomized Study of Zanubrutinib versus Bendamustine plus Rituximab (BR) in Patients with Treatment Naive (TN) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL / SLL)

This abstract from the American Society of Hematology Annual Meeting and Exposition (ASH 2021) presented interim results of the Phase 3 randomized SEQUOIA study which evaluated the efficacy and safety of zanubrutinib versus BR in previously untreated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL / SLL) patients without the high-risk mutation,17p deletion

Cookie	Duration	Description
cookielawinfo-checkbox-analytics	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional	11 months	The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy	11 months	The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.

Medications

Pirtobrutinib for Relapsed CLL After Covalent BTKi Therapy

Promising Results in Difficult-to-Treat CLL with Epcoritamab

Solid Results for Epcoritimab for Relapsed / Refractory CLL

Long-term Outcomes After Lenalidomide plus Rituximab for CLL

Spontaneous Remission of Chronic Lymphocytic Leukemia in a Patient with SARS-CoV-2

Immunotherapeutic Strategies in Chronic Lymphocytic Leukemia: Advances and Challenges

ASH 2021: BRUIN CLL-321: A Phase 3 Open-Label, Randomized Study of Pirtobrutinib Versus Investigator’s Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in BTK Inhibitor Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (Trial in Progress)

ASH 2021: Deep Profiling of Chronic Lymphocytic Leukemia (CLL) and Healthy Immune Cells By Mass Cytometry Resolves Impacts of Venetoclax Pressure

ASH 2021: SEQUOIA: Results of a Phase 3 Randomized Study of Zanubrutinib versus Bendamustine plus Rituximab (BR) in Patients with Treatment Naive (TN) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL / SLL)

CLL SOCIETY FAST FIND

QUICK LINKS

ABOUT CLL SOCIETY

CONTACT